Brian Gladsden, Mosaic Therapeutics CEO

Ex­clu­sive: On­col­o­gy start­up from Sanger In­sti­tute nabs $28M, ex-No­var­tis SVP as CEO

The Well­come Sanger In­sti­tute’s lat­est on­col­o­gy spin­out will en­ter the clin­ic in about 18 to 24 months with a new CEO at the helm and $28 mil­lion in Se­ries A funds.

Called Mo­sa­ic Ther­a­peu­tics, the start­up is work­ing on new tar­get­ed treat­ments from the labs of Sanger’s Math­ew Gar­nett and Sanofi board mem­ber Emile Voest, who works at the Nether­lands Can­cer In­sti­tute and On­code In­sti­tute. Al­so on the co-found­ing team is for­mer Sanger head of tech­nol­o­gy trans­la­tion Adri­an Ibrahim.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.